



LSX | WORLD CONGRESS

STRATEGY, INVESTMENT, PARTNERING &
COMMERCIALISATION FOR LIFE SCIENCE
EXECUTIVE LEADERS

Wifi Network: etcvenues
Password: wifi8020

6th Annual

4-5 February, 2020
133 Houndsditch, Liverpool St
London, UK

#lsxworld @lsxleaders

Organised by:

LSX | The network
for life science
executive leaders

Final programme correct as of 03.02.2020

LSX World Congress

Welcome

STRATEGY, INVESTMENT AND PARTNERING FOR LIFE SCIENCE EXECUTIVE LEADERS

Welcome to the LSX World Congress 2020!

We're delighted to be returning for the 6th annual edition of Europe's leading executive strategy, partnering and investment congress. #LSXWorld 2020 is the biggest and best yet with 1,000 life science CXOs, investors, pharma heads and key stakeholders registered and more speakers, company showcases and partnering meetings than ever before!

Now encompassing the **Medtech Leaders** and three **Biotech Leaders** tracks - **Capital Markets & Investment**, **Partnerships & Deal Making** and **Capital Deployment & Commercialisation Strategy** as well as Investable and Licenable showcases, CEO and Pharma BD Leaders forums and workshops, the LSX World Congress is the all-encompassing strategy event that addresses all c-suite challenges and opportunities!

As always, we retain our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience to bring together the people that matter to the future of healthcare and life sciences.

The LSX World Congress Team

#LSXWorld
www.lsxleaders.com/lxx-world-congress
@LSXLeaders

Wifi: etcvenues
Password: wifi8020



Turbocharge your onsite experience

We've built a mobile app for LSX World Congress!

It has all the important information you'll need for the event and features to enhance your onsite experience.

There is a whole host of benefits to downloading the app:

- ✓ Personalise your onsite agenda
- ✓ Set notifications for sessions you're interested in
- ✓ Book 1:1 meetings

Step 1: Download the App!

If you haven't already, download the app on the device you have with you today.

Search for "LSX Events" or LSX Events in the App store for iOS phones, or Google Play store for Android phones.

Step 2: Log In

Open up the app once downloaded and login using your name and the email you used when registering for the conference.

Step 3: Verify

When prompted, enter the verification code sent to your email account (check all folders) and away you go. Any questions, please ask a member of the LSX Team.

Having problems with the App? Visit our information and help desk at the registration point and speak to Rebecca Herne, Operations Manager.

Our Partners

PLATINUM PARTNERS



GOLD PARTNERS



GOLD PARTNERS



SILVER PARTNERS



SUPPORTING PARTNERS



ROOM: ENTERPRISE 2

9:00 Welcome Address
Josh Dance, *SVP, LSX*

9:10 Keynote Panel: A sustainable connected European ecosystem: Building and strategically financing long-term sustainable Biotechs and life science clusters

Moderator: Clive Cookson, *Science Editor, Financial Times*
Onno van de Stolpe, *CEO, Galapagos*
Debbie Harland, *Partner, SR One*
Craig Johnstone, *COO, Evotec*
Geraldine O’Keeffe, *Partner Public Equities, LSP*
Sean Marett, *Chief Business and Chief Commercial Officer, BioNTech*
Tim Luker, *Sr. Director External Innovation, Lilly*

10:10 Keynote Presentation: Where’s the money going? Capital Markets Outlook

Ben Thorpe, *Head of Healthcare Banking EMEA, Goldman Sachs*

10:30 Morning Break

ROOM: INTERACT

9:00 Welcome Address
Kiron Campbell, *Conference Director, LSX*

9:05 Keynote Panel: M&A, consolidations, new value propositions, and commercial leadership in Medtech

Moderator: Robbie McLaren, *Partner, Latham & Watkins*
Charity Kufaas, *VP Strategy & Business Development EMEA, Medtronic*
Hani Abouhalka, *Company Group Chairman - Medical Devices EMEA, Johnson & Johnson*
Rupert Winckler, *Head of EMEA New Business Development, Olympus*

9:45 Keynote Panel: Unpacking value-based healthcare and multi-stakeholder led value creation

Moderator: Stephen Dorrell, *Chairman, Dorson and LaingBuisson*
Frank Maddux, *Global CMO, Fresenius Medical Care*
Maarten Akkerman, *Vice President Medical Affairs and Value-Based Healthcare, Medtronic*
John E Milad, *CEO, Quanta Dialysis*
Richard di Benedetto, *President and EVP, Aetna International*

On Floor Showcases

Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv€\$table) and/or attract interest in a licensing deal (Lic€n\$able).

These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech.

Inv€\$table and Lic€n\$able are 15-minute showcase slots allowing companies to deliver succinct, hard-hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations.

Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.

Satellite Forums

Our extremely popular and always oversubscribed LSX Forums provide a unique, powerful and valuable space for the candid sharing of experiences, expertise and insight between industry peers. By invitation only, the four forums run throughout day one of the World Congress for Pharma BD heads, startup CEOs, private growth-stage CEOs and for publicly listed CEOs.

All forums are held under Chatham House Rule and include peer-review case studies from CEOs and co-host partners and a general discussion focused on brainstorming solutions to the collective challenges of the attendees.

ROOM: ONFLOOR SHOWCASE AREA

11:00 Biotech Inv€\$table Showcase Medtech Inv€\$table Showcase Lic€n\$able Showcase

ROOM: SYNERGY 2

11:00 PUBLIC CEO FORUM

Co-hosted by

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

ROOM: INTEGRATE 3

11:00 PHARMA BD LEADERS FORUM

Co-hosted by

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

ROOM: BALCONY

11:00 INNOVATION ZONE

Co-hosted by

ROOM: ENTERPRISE 2	ROOM: SYNERGY 1	ROOM: ENGAGE	ROOM: INTERACT
<p>12:05 Panel: Raising capital and diversity standards - addressing the imbalance</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Kyp Sirinakis, <i>Managing Partner, Epidarex Capital</i> Roel Bulthuis, <i>Managing Partner, Inkef</i> Rafaèle Tordjman, <i>Founder & CEO, Jeito</i> Maina Bhaman, <i>Partner, Sofinnova</i> Fiona de Hemptinne, <i>Venture Partner, UCB Ventures</i></p>	<p>12:05 Panel: Passing the baton - Success in M&A deal-making</p> <p>Moderator: Gregory Benning, <i>Managing Director, Head of Investment Banking, Back Bay Life Science Advisors</i> Luc Dochez, <i>Co-founder, Pharvaris and former CEO, Tusk Therapeutics</i> Phil L'Hullier, <i>Head of BD, Europe, European Innovation Hub, MSD</i> Andy Staples, <i>Head of Deal Finance, AstraZeneca</i></p>	<p>12:10 Fireside Chat: Regulatory assistance for Europe's life science SMEs</p> <p>Moderator: Ben Howlett, <i>Director, World Healthcare Journal</i> Constantinos Ziogas, <i>Head of SME Office, European Medicines Agency</i></p>	<p>12:05 Panel: Attracting the big strategics; what CVC need to see</p> <p>Moderator: Elizabeth Cairns, <i>Reporter, Vantage</i> Jonathan Goldstein, <i>Director, Corporate Research and Ventures, Boston Scientific</i> Assaf Barnea, <i>CEO, Sanara Ventures</i> Jeanne Bolger, <i>VP Venture Investments, Johnson & Johnson Innovation</i> Andreas Wuepper, <i>Director Investments, Europe, Fresenius Medical Care Ventures</i></p>
<p>12:45 Lunch Break</p>			
<p>13:45 Panel: Go big or go home? - evolving early investment strategies</p> <p>Moderator: Lisa Urquhart, <i>Editor, Vantage</i> Roger Franklin, <i>Partner, Hadean Ventures</i> Sara Secall, <i>Partner, INVEREADY</i> Montserrat Vendrell, <i>General Partner, Alta Life Sciences</i> Søren Lemonius, <i>Managing General Partner, Sunstone Life Science Ventures</i> Søren Møller, <i>Managing Partner, Novo Seeds</i></p>	<p>13:45 Panel: Positioning public partnerships - optimising deal-making when listed</p> <p>Moderator: Cody Powers, <i>Associate Principal, ZS</i> Renée Aguiar-Lucander, <i>CEO, Calliditas Therapeutics</i> Olav Hellebo, <i>CEO, ReNeuron</i> John Strafford, <i>VP, Head of BD, Silence Therapeutics</i> John Dawson, <i>CEO, Oxford BioMedica</i></p>	<p>13:45 Panel: Harnessing the drivers for success in your early stage programme</p> <p>Moderator: Carl Engleman, <i>Vice President, Cello Health Consulting</i> Caroline Barelle, <i>CEO, Elasmogen</i> Stuart Collinson, <i>CEO, Oxstem</i> Lars van der Veen, <i>COO, iOnctura</i></p>	<p>13:45 Panel: Commercial Success in Medtech through talent and team building</p> <p>Moderator: Kristien Esser, <i>CEO, Guided Solutions</i> Craig Marshall, <i>CEO, OrganOx</i> Christoph Ruedig, <i>Partner, Albion Capital</i> Simon Hubbert, <i>Chairman, Rhythm AI</i> Brian Howlett, <i>Non-Exec. Director, Accentus Medical, Angle, Oxford Endovascular</i> Maina Bhaman, <i>Partner, Sofinnova</i></p>
<p>14:25 Fireside Chat: An A+ mega round launch</p> <p>Moderator: Lisa Urquhart, <i>Editor, Vantage</i> Mark Altmeyer, <i>CEO, Arvelle Therapeutics</i></p>	<p>14:35 Fireside Chat: Going with your gut in Pharma co-development</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Simon Baeriswyl, <i>COO, Enterome</i></p>	<p>14:25 Fireside Chat: Building A(I), and deploying A big B</p> <p>Moderator: John Hodgson, <i>Independent Consultant</i> Tim Williams, <i>CEO, Healx</i></p>	<p>14:20 Panel: Learnings and lessons from early-stage fundraising success stories</p> <p>Moderator: Todd Usen, <i>CEO, Activ Surgical</i> Mark-Jan Harte, <i>CEO, Aidence</i> Ian Wilson, <i>CEO, ImaginAb</i> Rainer Strohmenger, <i>Managing Partner, Wellington Partners</i> Ena Prosser, <i>Partner, FH Partners</i></p>
<p>14:45 Panel: Making the grade - B+ rounds and investor alignment</p> <p>Moderator: Jonathan Gertler, <i>Founder & CEO, Back Bay Life Science Advisors</i> Hakan Goker, <i>Executive Investment Director, M Ventures</i> Giovanni Mariggi, <i>Partner, Medixci</i> Jack Nielsen, <i>MD, Vivo Capital</i> Thibaut Roulon, <i>Investment Director - Life Sciences, Bpifrance</i> Clara Campàs, <i>Partner, Asabys Partners</i></p>	<p>15:00 Fireside Chat: Crafting win/win early-stage Biotech-to-Biotech partnerships</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Cedric Ververken, <i>CEO, Confo Therapeutics</i></p>	<p>14:45 Panel: Early planning and effective capital deployment when progressing through the clinic</p> <p>Moderator: John Hodgson, <i>Independent Consultant</i> Joe Dupere, <i>CEO, Rexgenero</i> Leon Hooftman, <i>CMO, ISA Pharmaceuticals</i> Grace E. Colón, <i>CEO, InCarda Therapeutics</i> Juho Jalkanen, <i>CDO, Faron Pharmaceuticals</i></p>	<p>14:55 Panel: Together we rise; tips and tricks for Healthtech partnerships</p> <p>Moderator: Roy Wiesner, <i>Managing Director, aMoon Fund</i> Brian Hakim, <i>Director of BD, MedTecX</i> Seamus Browne, <i>Head of Industry Partnerships, Royal College of Surgeons</i> Sascha Alilovic, <i>Partner, SHS Capital</i> John Power, <i>CEO, Aerogen</i></p>
<p>15:30 Afternoon Break</p>			

ROOM: ONFLOOR SHOWCASE AREA	ROOM: SYNERGY 2	ROOM: INTEGRATE 3	ROOM: BALCONY
<p>Biotech Inv€\$table Showcase Medtech Inv€\$table Showcase</p> <p>12:15  </p> <p>12:30  </p>	<p></p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>	<p></p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>	<p></p>
<p>12:45 Lunch Break</p>			
<p>13:45 Biotech Inv€\$table Showcase Medtech Inv€\$table Showcase Cardio Metabolic</p> <p>13:45   </p> <p>14:00   </p> <p>14:15   </p> <p>14:30   </p> <p>14:45   </p> <p>15:00   </p> <p>15:15   </p> <p>15:30   </p> <p>15:45   </p>	<p>13:45 </p> <p>Co-hosted by </p> <p></p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>	<p>13:45 </p> <p>Co-hosted by </p> <p></p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>	<p>13:45 </p> <p>Co-hosted by </p>

ROOM: ENTERPRISE 2

ROOM: INTERACT

16:00

16:00

Afternoon Keynote: Ad-vant-ages in building a Biotech family

Fireside Chat: Company building and the journey to acquisition

Moderator: **Melanie Senior**, Analyst and Specialist Writer, Life Sciences
Matthew Gline, CFO, Roivant Sciences

Moderator: **Tina Tan**, Executive Editor, FirstWord Medtech
Peter Ullrich, CEO, Titan Spine

16:20

16:20

Afternoon Keynote Panel: In conversation with pharma leaders - Innovation, efficiency and technology convergence

Panel: Key Learnings from the M&A Market

Moderator: **Ben Thorpe**, Head of Healthcare Banking EMEA, Goldman Sachs
Ivana Magovčević-Liebisch, CBO, Ipsen
Nigel Sheail, Global Head of M&A and BD&L, Novartis
Philippe Lopes-Fernandes, SVP, Global Head of BD and Alliance Management, Merck KGaA
Ben Thorner, SVP, Global Business Development, MSD

Moderator: **Mark Andrews**, Managing Director, Pharma Ventures
Peter Ullrich, CEO, Titan Spine
Eline Vrijland-Van Beest, Co-Founder, Nightbalance
Chas Taylor, CEO, Veryan Medical
Vanessa Vankerckhoven, CEO and Co-Founder, Novosanis
Andrew Glass, Regional Director Northern Europe, Abbott

17:00

17:00

Closing Keynote Panel: R&D and the PRC - Regulatory reform, partnering and advancing development in China

Panel: The making of Medtech leaders; from fundraising to upscaling

Moderator: **Sam Fazeli**, Head of European Research, Pharmaceuticals Analyst, Bloomberg
Mirko Scherer, CEO, CoFeS China
Zishan Haroon, Managing Partner, Julz Co
Richard Yang, Director of Pharmacovigilance Operations, Fountain Medical Development
Guillaume Vignon, SVP Business Development, BeiGene
Donald Xu, Managing Partner, Lynx Financial

Moderator: **Michael Branagan-Harris**, CEO, Device Access UK
Martin Frost, Founder & Non-Executive Director, CMR Surgical
Bernard Ross, CEO, Sky Medical Technology
Eliane Schutte, CEO, Xeltis
Steve Swinson, Chair, Comphy and Tibbyah Holdings, Former Chair, Acteon, Vexim, Bone Therapeutics

ROOM: EXHIBITION AREA

17:45

Networking Party

HOSTED BY:



18:30

Investor Dinner

If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

ROOM: ONFLOOR SHOWCASE AREA

ROOM: SYNERGY 2

ROOM: BALCONY

16:00

Biotech Inv€\$table Showcase

Medtech Inv€\$table Showcase

Biotech Inv€\$table Showcase

16:00



Co-hosted by



This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.



Co-hosted by



16:00



16:15



16:30



16:45



17:00



17:15



17:30



ROOM: EXHIBITION AREA

17:45

Networking Party

HOSTED BY:



18:30

Investor Dinner

If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

ROOM: ENTERPRISE 2

9:25 Welcome Address
Josh Dance, SVP, LSX

9:35 Keynote Panel: The listing consideration - building on roots or the American dream?
Moderator: Isabella Schidrich, Managing Director, Nasdaq
Anthony Pagano, SVP Finance and Corporate Development, Genmab
Kevin Lee, CEO, Bicycle Therapeutics
Sean Marett, Chief Business and Chief Commercial Officer, BioNTech
Christophe Douat, CEO, MedinCell

10:30 Morning Break

ROOM: ENTERPRISE 2

11:00 Capital Markets & Investment

11:00 Track Keynote Panel: China's integration into global, the global pharma science and what this means for raising capital in Asia
Karen Liu, Partner, 3E BioVentures

11:20 Panel: New capital & growth - Asian investment into European life sciences
Moderator: Ari Silverman, Partner, Mavie Technologies
Katherine Cohen, Venture Partner, Panacea Venture
Peter Bisgaard, Managing Director, Nan Fung Life Sciences
Marietta Wu, Managing Director, Quan Capital
Frank Yu, CEO, Ally Bridge Group

12:00 Fireside Chat: Mapping, supporting and financing European innovation and entrepreneurship
Moderator: Mick Cooper, Analyst, Trinity Delta
Adelaide Cracco, Head of Life Sciences, European Investment Fund

ROOM: SYNERGY 1

11:00 Partnerships & Deal Making

11:00 Building a Biotech unicorn from scratch through partnerships
Jens Hennecke, Chief Business Officer, SOTIO/PPF Group

11:20 Panel: Are we there yet? Navigating the roadmap in early-stage partnerships
Moderator: Adrian Dawkes, Managing Director, PharmaVentures
Tomas Landh, Innovation Sourcing Vice President, Senior Principal Scientist of Search and Evaluation, Novo Nordisk
Sergio Capancioni, Director S&E Western Europe, AbbVie
Catherine Pickering, CEO, iOnctura
Rick Davis, Senior Director, New Ventures and Transactions, Oncology, Johnson & Johnson

ROOM: ENGAGE

11:00 Capital Deployment & Commercialisation Strategy

11:00 Panel: Going it alone - Challenges and late-stage capital deployment in self-commercialisation
Moderator: Carl Engleman, Vice President, Cello Health Consulting
Carl Sterritt, CEO, Shield Therapeutics
Erik van den Berg, CEO, AM-Pharma
Eduardo Bravo, CEO, Nordic Nanovektor
Kieran Rooney, VP Strategic Alliances and Licensing, Amryt Pharma

ROOM: INTERACT

11:00 Medtech Leaders

11:00 Panel: Creating empowered, technologically enabled Healthtech consumers
Moderator: Michael Branagan-Harris, CEO, Device Access UK
Frances A. Ayalasonmayajula, Head of Population Health, HP
Richard di Benedetto, President, Aetna
Steve Atkinson, CEO, Atlantic Therapeutics
Ben Maruthappu, CEO, Cera
Victoria Betton, Founder, mHabitat, CIO, Mindwave Ventures

11:40 Fireside Chat: At the intersection of digitisation and value-based care
Moderator: David Germonpré, Partner, MTIP
Robbie Hughes, CEO, Lumeon

12:00 Panel: Successfully navigating regulatory change; strategies responses to MDR and IVDR
Moderator: Amanda Maxwell, European Reg. Affairs Director, Medtech Insight
David Tuch, CEO, Lightpoint Medical
Susana de Azevedo Wäsch, VP Quality Management & Regulatory Affairs, Ypsomed AG
James Pink, Senior Director, NSF International
Robert Abbott, VP, Chief Legal Counsel EMEA, Stryker
Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI Group

On Floor Showcases

Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv€\$table) and/or attract interest in a licensing deal (Lic€n\$able).

These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech.

Inv€\$table and Lic€n\$able are 15-minute showcase slots allowing companies to deliver succinct, hard hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations.

Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.

ROOM: ONFLOOR SHOWCASE AREA

11:00 Biotech Inv€\$table Showcase



Satellite Workshops

The workshops are intimate 90-minute interactive education forums in which CXOs are navigated through considerations, strategy and ideas for approaching key company milestones by an expert partner. The workshops run throughout day two of the World Congress covering M&A, clinical strategies, licensing & collaboration and market access.

ROOM: SYNERGY 2 | ROOM: INTEGRATE 3 | ROOM: BALCONY



Co-hosted by



This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Additional seats may be available on first-come first-served basis.



Co-hosted by



This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Additional seats may be available on first-come first-served basis.



Co-hosted by



ROOM: ENTERPRISE 2

ROOM: SYNERGY 1

ROOM: ENGAGE

ROOM: INTERACT

12:20

Panel: PIPEs, pipelines and public equities
 Moderator: **Mick Cooper**, Analyst, Trinity Delta
Mattias Häggblom, Fund Manager, Swedbank Robur
Geraldine O’Keeffe, Partner Public Equities, LSP
Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience
Marek Poszepczynski, Portfolio Manager - International Biotechnology Trust, SV Health Investors

12:10

Panel: Platforms and partnerships
 Moderator: **Andy Smith**, Analyst, Equity Development
Yochi Slonim, CEO, Anima Biotech
Tim Luker, Sr. Director External Innovation, Lilly
Jane Dancer, CBO, F-Star
Giuseppe Mazza, CEO, Engitix
Mike Romanos, CEO, Microbiotica

11:50

Panel: The I in team - CEO strategy in C-Suite management & board development
 Moderator: **Melanie Senior**, Analyst & Specialist Writer, Life Sciences
Don DeBethizy, Director, Argenx and Chair to European biotechs
Sarah Shackleton, Partner, Marketing & Talent, Abingworth
Edwin Moses, former CEO, Ablynx
Denise Scots-Knight, CEO, Mereo Biopharma
Annalisa Jenkins, Chair to European biotechs

12:40

Fireside Chat: Fundraising and the real-world value in therapeutic AI
 Moderator: **Bill Aronson**, COO, AI Research Group
Marc Julien, Co-CEO, Diabeloop

13:00

Lunch Break

ROOM: ENTERPRISE 2

ROOM: INTERACT

14:00

Afternoon Keynote Panel: Health technology convergence - Driving the next wave of value in healthcare
 Moderator: **Andy Smith**, Analyst, Equity Development
Anoop Maini, CEO, Excite Ventures
Sumit Nagpal, CEO and Co-Founder, CareFully
Junaid Bajwal, Global Lead for Strategic Alliances, MSD

14:00

Growing opportunity, growing threat; cyber-security in the context of digitisation
 Moderator: **Bill Aronson**, COO, AI Research Group
Leon Lerman, CEO, Cynerio
Saif Abed, Founding Partner, AbedGraham, Cyber Security Expert, European Commission and WHO
Jovan Stevovic, CEO, Chino.io

14:45

Fireside Chat: Now and then - The true impact of AI on life sciences & realising AI potential
Mark O’Herlihy, Managing Director EMEA, IBM Watson Health

14:40

Panel: Healthtech’s reimbursement challenge in the digital age
 Moderator: **Prof. Brian D Smith**, Principal Advisor, Pragmedic
Daniel O’Mahony, Partner, Seroba Life Sciences
Luella Trickett, Director Value and Access, Association of British HealthTech Industries
Rudy Dekeyser, Managing Partner, LSP Health Economics Fund
Paul Brown, CFO, NW London CCGs, NHS
Ali Hasan, Chief Medical and Health Officer, Vitality

15:10

Closing Keynote Panel: Realising AI’s potential in life sciences and healthcare
 Moderator: **John Hodgson**, Independent Consultant
Derk Arts, CEO, Castor
Bharat Tewarie, Former EVP & CMO, UCB
Alison Howie, Chief Product Officer, IXICO
Parker Moss, Board Member, CRUK

15:30

Closing Keynote Panel: Mapping Medtech’s future - New opportunities in collaboration and innovation
 Moderator: **Prof. Brian D Smith**, Principal Advisor, Pragmedic
Fredrik Strömberg, Senior Regional Director Northern Europe, Nobel Biocare
Edward Cox, Digital Therapeutics CEO and Thought Leader, Dthera Sciences
Christoffer-Martin Seubert, Lead for Strategic Alliances, Digital Health, Teamplay Platform, Siemens Healthineers
Richard Kivel, Managing Director, GrayBella Capital
Julie Bretland, CEO, Our Mobile Health

16:00

Close of Congress

16:20

Close of Congress


Satellite Sessions



A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmen of listed life science and healthcare companies. The forum will feature peer-reviewed CEO and partner case studies, and an interactive general discussion.

The Public CEO Forum is open only to life sciences companies listed on the public markets. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:



Timings:

Feb 4, 11:00 - 12.45 - Synergy 2

Case Studies

Moderator:

Philip Broke, Partner, White & Case

Case Study 1: ESG & Changes in Regulatory Environment

Assaf Homossany, MD-EMEA, Nasdaq

Case Study 2: PIPEs deals and preparing for a US Listing

Philip Broke, Partner, White & Case

Case Study 3: Gilead/Galapagos Alliance

Onno Van de Stolpe, CEO, Galapagos



A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmen of private life science and healthcare companies. The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.

The Private CEO Forum is only open to post series A private biotech companies. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:



Timings:

Feb 4, 13:45 - 15.30 - Synergy 2

Case Studies

Moderator:

Andrew Harrow, Partner, Goodwin

Case Study 1: Considerations and planning for going public in the US

Assaf Homossany, MD-EMEA, Nasdaq

Case Study 2: Crossover Fundraising Strategies

Sophie McGrath, Partner, Goodwin

Case Study 3: Successful US fundraising and IPOs

Matt Gline, CFO, Roivant



A Chatham House Rule, invite-only forum for CEOs of life science and healthcare startups.

The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.

The Private CEO Forum is only open to pre-series A private biotechs and spinouts of our TTO partners. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

Co-Hosts:



Timings:

Feb 4, 16:00 - 17.45 - Synergy 2

Case Study Roundtable

Moderated discussion: How to approach and build relationships with VCs

Nicholas Ibery, Member of the Investment Committee, NCL Technology Venture
Claire Brown, Investment Director, BioCity

Term Sheet Workshop: Key VC terms and all you need to know on a term sheet.

James Baillieu, Partner, Bird & Bird



Timings:

Feb 5, 11:00 - 12.30 - Synergy 2

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.

Co-Hosts:



Timings:

Feb 5, 11:00 - 12.30 - Integrate 3

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.

Co-Hosts:



Showcase Profiles



Presenter: Catherine Schreiber, Dep. CEO

Market/Indication:

World's first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance.

Funding Stage: Early Growth, Growth

Development Stage: On the Market, Clinical

Location: Germany

Track: Inv€\$table Medtech

Day and Time: Day 1, 17.00



Presenter: Michel Finance, CEO

Market/Indication:

Affluent Medical focuses on breakthrough therapies with a new approach of medical devices.

Funding Stage: Late Growth

Development Stage: Clinical

Location: France

Track: Inv€\$table Medtech

Day and Time: Day 1, 12.00



Presenter: Egill Masson, CEO

Market/Indication:

Development of therapeutics which enhance and deploy the body's own innate microbial defence mechanisms to combat debilitating infectious diseases.

Funding Stage: Seed

Development Stage: Drug Discovery, Pre-Clinical

Location: Iceland

Track: Inv€\$table Biotech

Day and Time: Day 1, 11.00



Presenter: Claudia Jimenez, General Manager

Market/Indication:

Proprietary and patent protected technologies to boost the production of recombinant proteins using Baculovirus vector expression systems (BVES) in insect cells.

Funding Stage: Growth

Development Stage: Filing / Reg. Approval

Location: Spain

Track: Inv€\$table Biotech

Day and Time: Day 1, 12.00



Presenter: David Mazzo, CEO

Market/Indication:

Late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies

Funding Stage: Publicly Listed

Ticker: NASDAQ:CLBS

Development Stage: Phase II

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 2, 12.30



Presenter: Ajan Reginald, CEO

Market/Indication:

Devoted to discovering breakthrough medicines that change the standard of medical care for patients.

Funding Stage: Private

Development Stage: Phase II

Location: United Kingdom

Track: Cardio Metabolic

Day and Time: Day 1, 14.15



Presenter: Gaudenz von Capeller, CFO

Market/Indication:

Pritavely-owned Biopharma - patented small molecule drug with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.

Funding Stage: Early Growth

Development Stage: Phase I

Location: Switzerland

Track: Inv€\$table Biotech

Day and Time: Day 1, 17.15



Presenter: Celia Belline, CEO

Market/Indication:

To accelerate the development of novel therapies to prevent and treat hearing loss, tinnitus, and otitis

Funding Stage: Growth, Private

Development Stage: Pre-Clinical, Phase I, Phase II

Location: France

Track: Inv€\$table Biotech

Day and Time: Day 1, 16.30



Presenter: Myles Greenberg, President & CEO

Market/Indication:

Transforming the way vascular disease is treated, naturally, with Natural Vascular Scaffolding™ (NVS).

Funding Stage: Early Growth

Development Stage: Clinical, In Development

Location: United States

Track: Inv€\$table Medtech

Day and Time: Day 1, 13.45



Presenter: Yochi Slonim, Co-Founder & CEO

Market/Indication:

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation.

Funding Stage: Early Growth

Development Stage: Pre-Clinical

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 1, 16.15



Presenter: Andy Yates, CSO

Market/Indication:

Endocannabinoid system modulation - oncology and cancer associated anorexia, IBD, rare diseases

Funding Stage: Publicly Listed

Ticker: NASDAQ: ARTL

Development Stage: Phase II

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 1, 15.15



Presenter: Michael Malkoch, CEO

Market/Indication:

The most innovative fixation technology of bone fractures resulting in higher surgical success rate, faster recovery time and less pain suffering.

Funding Stage: Seed, Early Growth

Development Stage: Clinical, In Development

Location: Sweden

Track: Inv€\$table Medtech

Day and Time: Day 1, 15.00



Presenter: Jon H.Hoem, CEO & Co-Founder

Market/Indication:

The first medical device to diagnose and be a treatment platform for microvascular obstruction in heart attack patients

Funding Stage: Early Growth

Development Stage: Phase I

Location: Switzerland

Track: Inv€\$table Medtech

Day and Time: Day 1, 16.00



Presenter: Cristianne Rijcken, Founder & CSO

Market/Indication:

Targeted nanomedicines with superior therapeutic profiles for the treatment of cancer

Funding Stage: Growth, Private

Development Stage: Phase II

Location: Netherlands

Track: Licensable Biotech

Day and Time: Day 1, 11.30



Presenter: Neil Clark, CEO

Market/Indication:

Anti-infectives that prevent infection and improve outcomes for patients

Funding Stage: Publicly Listed

Ticker: LON: DEST

Development Stage: Drug Discovery, Phase II

Location: United Kingdom

Track: Inv€\$table Biotech

Day and Time: Day 1, 14.15



Presenter: Ulf Hannelius, President & CEO

Market/Indication:

Develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule.

Funding Stage: Publicly Listed

Ticker: FRA:DMN

Development Stage: Phase I, Phase II

Location: Sweden

Track: Inv€\$table Biotech

Day and Time: Day 1, 14.30



Presenter: Pascal Neuville, CEO

Market/Indication:
Transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of CNS diseases and cancer.

Funding Stage: Early Growth, Private
Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II
Location: France

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.15



Presenter: Philip Huxley, CEO

Market/Indication:
Pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease.

Funding Stage: Seed
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Licensable Biotech
Day and Time: Day 1, 11:15



Presenter: Shlomi Raz, CEO

Market/Indication:
Dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity

Funding Stage: Early Growth
Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 12.15



Presenter: Juho Jalkanen, CDO

Market/Indication:
Clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.

Funding Stage: Growth
Development Stage: Phase II
Location: Finland

Track: Licensable Biotech
Day and Time: Day 1. 11.00



Presenter: Adam Robertson, CSO

Market/Indication:
Developing pharmaceuticals to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing compounds that are highly effective in treating these tumors.

Funding Stage: Seed
Development Stage: Drug Discovery, Pre-Clinical
Location: Norway

Track: Inv€\$table Biotech
Day and Time: Day 1, 11.30



Presenter: Sijme Zeilemaker, COO

Market/Indication:
Novel immuno-oncology approach to treat solid tumours through its lead program Ilixadencel.

Funding Stage: Publicly Listed
Ticker: STO: IMMU
Development Stage: Phase II
Location: Sweden

Track: Inv€\$table Biotech
Day and Time: Day 1, 14.00



Presenter: Orest Lastow, CEO

Market/Indication:
ICONOVO is a Swedish privately funded device company with a business model to supply the market with unique, safe and cost efficient inhalation devices.

Funding Stage: Growth
Development Stage: Filing / Reg. Approval, Clinical, In Development
Location: Sweden

Track: Inv€\$table Medtech
Day and Time: Day 1, 12.15



Presenter: Grace E. Colón, President & CEO

Market/Indication:
Novel approach of treating cardiovascular conditions by the inhalation route.

Funding Stage: Early Growth, Private
Development Stage: Phase II
Location: United States

Track: Inv€\$table Biotech
Day and Time: Day 2, 12.00



Presenter: Pete O'Heeron, CEO

Market/Indication:
Regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts.

Funding Stage: Early Growth, Private
Development Stage: Phase II
Location: United States

Track: Licensable Biotech
Day and Time: Day 1, 11.45



Presenter: Jan Alenfall, CEO

Market/Indication:
Our research and development is currently focused on the stimulation of hair growth and diabetes.

Funding Stage: Early Growth
Development Stage: Drug Discovery, Phase II
Location: Sweden

Track: Cardio Metabolic
Day and Time: Day 1, 15:15



Presenter: Michael Pehl, CEO

Market/Indication:
Discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients

Funding Stage: Seed, Private
Development Stage: Pre-Clinical, Phase I
Location: Germany

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.30



Presenter: Lorenzo Pradella, CEO

Market/Indication:
GreenBone is a leading bone regeneration company founded in 2014 addressing high unmet medical needs in the field of orthopaedics and bone diseases.

Funding Stage: Growth
Development Stage: Filing / Reg. Approval, Clinical
Location: Italy

Track: Inv€\$table Medtech
Day and Time: Day 1. 11.00



Presenter: Andrew Woodland, CSO

Market/Indication:
We are discovering the next generation of therapies for skin diseases, including eczema, non-melanoma skin cancers and orphan skin diseases.

Funding Stage: Seed
Development Stage: Drug Discovery
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 17.30



Presenter: Richard Boyd, CEO

Market/Indication:
Improving outcomes for patients on dialysis, and other extra-corporeal treatments

Funding Stage: Early Growth
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1, 12.30



Presenter: David Tuch, CEO

Market/Indication:
The company develops and markets molecular imaging and sensing technologies to enable surgeons to detect cancer in real time during surgery and improve health outcomes for cancer patients.

Funding Stage: Growth
Development Stage: Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1. 15.45



Presenter: Veronica Gambillara Fonck, CEO

Market/Indication:
Translating novel scientific concepts into early proof of concepts for both the prevention and treatment of life-threatening diseases.

Funding Stage: Seed
Development Stage: Drug Discovery
Location: Switzerland

Track: Inv€\$table Biotech
Day and Time: Day 1, 16.00



Presenter: Oren Glanz, CEO

Market/Indication:

We are a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat severe diseases.

Funding Stage: Seed

Development Stage: Drug Discovery, Pre-Clinical

Location: Israel

Track: Cardio Metabolic

Day and Time: Day 1, 14.30



Presenter: Leonie De Best, CBO

Market/Indication:

Pre-clinical stage biotech company, developing novel antibiotics, so called Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat a wide variety of (resistant) bacterial infections.

Funding Stage: Seed

Development Stage: Pre-Clinical

Location: Netherlands

Track: Inv€\$table Biotech 2

Day and Time: Day 1, 16:15



Presenter: John Burt, CEO

Market/Indication:

Medherant has built upon its founders' world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch® drug delivery technology.

Funding Stage: Early Growth

Development Stage: Pre-Clinical

Location: United Kingdom

Track: Inv€\$table Medtech

Day and Time: Day 1, 11.30



Presenter: Christina Herder, EVP, COO

Market/Indication:

Medivir is a drug discovery and development company focusing on transformative cancer drugs.

Funding Stage: Publicly Listed

Ticker: STO: MVIR-B

Development Stage: Phase I, Phase II

Location: Sweden

Track: Inv€\$table Biotech

Day and Time: Day 1, 15.00



Presenter: Natalia Perekhvatova, CEO

Market/Indication:

Rapid development of break-through pharmaceutical products based on mitochondria targeted antioxidants.

Funding Stage: Growth

Development Stage: Phase III

Location: Luxembourg

Track: Cardio Metabolic

Day and Time: Day 1, 14.00



Presenter: Brian Shields, CEO

Market/Indication:

Minimally invasive hand-held radio-frequency device which ENT surgeons will use to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.

Funding Stage: Early Growth

Development Stage: Clinical,

Location: Ireland

Track: Inv€\$table Medtech

Day and Time: Day 1, 16.15



Presenter: Lorenzo Rossi, CEO

Market/Indication:

Newronika builds innovative brain devices based on its large knowledge on biosignal decoding

Funding Stage: Early Growth

Development Stage: Filing / Reg. Approval, Clinical

Location: Italy

Track: Inv€\$table Medtech

Day and Time: Day 1, 15.15



Presenter: Ewen Northwood, Director

Market/Indication:

NirVisio is developing and will commercialise a family of Near Infra-Red (NIR) imaging devices that will transform dental healthcare by improving the detection and monitoring of dental caries

Funding Stage: Pre-Seed

Development Stage: Pre-Clinical

Location: United Kingdom

Track: Inv€\$table Biotech

Day and Time: Day 2, 11.45



Presenter: Begüm Utz, Product Manager

Market/Indication:

Improving the diagnosis, treatment and prevention of acute neurodegenerative conditions and is currently focused on developing a diagnostic kit for the detection of Traumatic Brain Injury.

Funding Stage: Early Growth

Development Stage: Phase II

Location: Finland

Track: Inv€\$table Medtech

Day and Time: Day 1, 16.45



Presenter: Konstantin Chernov, CEO

Market/Indication:

We investigate transport- and binding functions of albumin in the blood with the aim to improve the diagnostic of life-threatening diseases

Funding Stage: Early Growth, Private

Development Stage: Pre-Clinical, Filing /

Reg. Approval, On the Market, Clinical, In

Development

Location: Germany

Track: Inv€\$table Medtech

Day and Time: Day 1, 17.30



Presenter: Barry Sharples, Chairman

Market/Indication:

Focused out of the public eye for 7 years, developing what we believe to be a paradigm shift in stem cell science.

Funding Stage: Growth, Private

Development Stage: Pre-Clinical,

Phase I/II

Location: United Kingdom

Track, Day and Time: Inv€\$table Biotech,

Day 1, 11.15, Cardio Metabolic, Day 1, 15.00



Presenter: Mike Romanos, CEO

Market/Indication:

Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota.

Funding Stage: Early Growth

Development Stage: Drug Discovery,

Pre-Clinical

Location: United Kingdom

Track: Inv€\$table Biotech

Day and Time: Day 1, 14.45



Presenter: Denis Dufrane, CSO / Co-Founder

Market/Indication:

Novadip has developed a unique tissue regeneration platform capable of generating multiple product classes to transform the lives of patients with limited or no effective treatment options.

Funding Stage: Private

Development Stage: Phase II

Location: Belgium

Track: Inv€\$table Biotech

Day and Time: Day 2, 11.00



Presenter: David Urech, CEO

Market/Indication:

Offering cutting-edge discovery of ready-to-develop multispecific biotherapeutics to partners.

Funding Stage: Growth

Development Stage: Drug Discovery,

Pre-Clinical, Phase I

Location: Switzerland

Track: Inv€\$table Biotech 2

Day and Time: Day 1, 16:30



Presenter: Hanooh Markshied, CEO

Market/Indication:

Innovative sealants and surgical patches based on unique combinations of advanced bioactive materials and optimized, electrospun nanofiber matrices.

Funding Stage: Early Growth

Development Stage: Clinical

Location: Israel

Track: Inv€\$table Medtech

Day and Time: Day 1, 11.15



Presenter: Martin Olovsson, CEO

Market/Indication:

The OnDosis device offers a new way to deliver prescription treatment: integrating medicine with intelligent dosing.

Funding Stage: Seed, Early Growth

Development Stage: Filing, Reg.

Approval, In Development

Location: Sweden

Track: Inv€\$table Medtech

Day and Time: Day 1, 14.30

ORYZON**Presenter:** Carlos Buesa, CEO**Market/Indication:**
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.**Funding Stage:** Publicly Listed
Development Stage: Phase II
Ticker: BME: ORY
Location: Spain**Track:** Inv€\$table Biotech
Day and Time: Day 1, 15.30**Otttek****Presenter:** Yoav Lichtenstein, CEO**Market/Indication:**
State-of-the-art innovative practical GI endoscopy solutions, Versatile, on-demand, easy-to-assemble, cost-effective, colonoscopy assist device.**Funding Stage:** Seed
Development Stage: In development
Location: Israel**Track:** Inv€\$table Medtech
Day and Time: Day 1, 16.30

OXSTEM

Presenter: Stuart Collinson, CEO**Market/Indication:**
OxStem is developing small molecule therapeutics targeting innate regeneration and repair.**Funding Stage:** Early Growth
Development Stage: Drug Discovery
Location: United Kingdom**Track:** Cardio Metabolic
Day and Time: Day 1, 14.45**Presenter:** Julian Howell, Co-Founder & CEO**Market/Indication:**
We are an early-stage research and development company — our mission is to save kidneys and prevent pain in people with Cystinuria.**Funding Stage:** Seed
Development Stage: Pre-Clinical
Location: United Kingdom**Track:** Inv€\$table Biotech
Day and Time: Day 2, 12.15**Presenter:** Nawal Ouzren, CEO**Market/Indication:**
Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.**Funding Stage:** Publicly Listed
Ticker: ENX:ALSEN
Development Stage: Pre-Clinical, Phase II
Location: France**Track:** Inv€\$table Biotech 2
Day and Time: Day 1, 16.00**Sisaf****Presenter:** Suzanne Saffie-Siebert, CEO**Market/Indication:**
ProSilic® is our bio-courier engineered to maximise the therapeutic benefits of drug molecules and active ingredients.**Funding Stage:** Growth
Development Stage: Pre-Clinical
Location: United Kingdom**Track:** Inv€\$table Biotech
Day and Time: Day 1, 17.00**SkyLabs****Presenter:** Jack Lee, CEO**Market/Indication:**
Ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life.**Funding Stage:** Early Growth
Development Stage: Phase III, Filing / Reg. Approval
Location: South Korea**Track:** Inv€\$table Medtech
Day and Time: Day 1, 14:45**Presenter:** Halvor Celius, CEO**Market/Indication:**
SonoClear is developing a product for enhanced ultrasound image quality in brain tumor surgery, providing the neurosurgeon with a powerful tool to achieve complete tumor removal.**Funding Stage:** Seed / Private
Development Stage: In Development
Location: Norway**Track:** Inv€\$table Medtech
Day and Time: Day 1, 15.30**Presenter:** Ivo Timmermans, CEO**Market/Indication:**
Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine.**Funding Stage:** Seed
Development Stage: Pre-Clinical
Location: Netherlands**Track:** Inv€\$table Biotech
Day and Time: Day 1, 15.45**ResoTher Pharma****Presenter:** Lone Veng, CEO**Market/Indication:**
Focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy**Funding Stage:** Early Growth
Development Stage: Drug Discovery, Pre-Clinical
Location: Denmark**Track:** Cardio Metabolic
Day and Time: Day 1, 15.45**Presenter:** Mark Rushworth, MD**Market/Indication:**
SageTech has developed a comprehensive way to capture, extract and purify volatile anaesthetic gases to PhEur monograph standard.**Funding Stage:** Seed
Development Stage: Filing / Reg. Approval, Clinical
Location: United Kingdom**Track:** Inv€\$table Medtech
Day and Time: Day 1, 14.00**Presenter:** Cliff Holloway, CEO**Market/Indication:**
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body's own immune system.**Funding Stage:** Publicly Listed
Ticker: LON: SCLP
Development Stage: Pre-Clinical, Phase I, Phase II
Location: United Kingdom**Track:** Inv€\$table Biotech
Day and Time: Day 1, 16.45**Presenter:** Andrew Parker, CEO**Market/Indication:**
Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for the treatment of auto-immune diseases.**Funding Stage:** Early Growth
Development Stage: Pre-Clinical
Location: France**Track:** Inv€\$table Biotech
Day and Time: Day 1, 11.15**Presenter:** Attila Borbath, CEO**Market/Indication:**
We are pioneering optoelectronics for neurostimulation medical devices by developing innovations to provide a powerful and versatile neurostimulation technological platform.**Funding Stage:** Growth
Development Stage: Pre-Clinical
Location: Belgium**Track:** Inv€\$table Medtech
Day and Time: Day 1, 11:45**Presenter:** Nikolaos Deliolanis, CEO**Market/Indication:**
Thericon is the first to bring multiparametric imaging to the operating theater. This allows for displaying of previously invisible tissue properties together with standard color images on a single screen.**Funding Stage:** Seed, Private
Development Stage: Clinical, In Development
Location: Germany**Track:** Inv€\$table Medtech
Day and Time: Day 1, 17.15**Presenter:** David Yudovich, CEO**Market/Indication:**
Full scope gene editing analysis solution that combines proprietary sequencing algorithms together with cost-effective, immediate access, and rapid turnaround sample processing services.**Funding Stage:** Seed
Development Stage: Pre-Clinical, On the Market, In Development
Location: Sweden**Track:** Inv€\$table Biotech
Day and Time: Day 1, 12.30



Presenter: Michael Stein, CEO

Market/Indication: Immuno-oncology company developing novel, rapidly adaptable therapeutic cancer immunotherapies using its patented PeptiCRAd and PeptiENV platforms.

Funding Stage: Early Growth
Development Stage: Pre-Clinical
Location: Finland

Track: Inv€\$table Biotech
Day and Time: Day 1, 16.45



Presenter: Piers Morgan, CFO

Market/Indication: Focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases.

Funding Stage: Publicly Listed
Ticker: AIM:VRP
Development Stage: Phase II
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 13.45



Presenter: Vincent Forster, CEO

Market/Indication: Versantis develops a new generation of liver disease therapeutics and diagnostics.

Funding Stage: Growth
Development Stage: Phase I
Location: Switzerland

Track: Cardio Metabolic
Day and Time: Day 1, 15.30



Presenter: Eliane Schutte, CEO

Market/Indication: Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy.

Funding Stage: Growth
Development Stage: Clinical
Location: Netherlands / Switzerland

Track: Inv€\$table Medtech
Day and Time: Day 1, 14:15



HOSTED BY:
 **MSD**
 INVENTING FOR LIFE

The Digital Poster Innovation Zone hosted by MSD runs across both days and is an opportunity to connect with and explore the next generation of bio and medical technologies being developed by entrepreneurs from across Europe's leading TTOs. Digital posters can be viewed at any time throughout the conference.

Discover the life science executive leaders of tomorrow!













Onsite Networking Opportunities

Networking Party



What's an event without some fun? The World Congress networking party on the evening of day one is the perfect opportunity to unwind, let your hair down and informally network with the community.

Relax, network and make unexpected connections over a drink (or few!).

HOSTED BY:  **ResoluteAI**
- connect to discover -

Investor Dinner



If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue for a gourmet 3-course networking dinner. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sell out.

1:1 Partnering



Maximise your out-of-session networking time and secure those vital face-to-face meetings. The partnering system went live with your profile filled in from the information provided on registration and allows you to search for potential partners and book meetings in the extensive 1-2-1 partnering area.

HOSTED BY:  **BeiGene**

Industry Leading Events for the Life Science C-suite



21-22 April 2020, etc. venues, 133 Houndsditch, London, UK
www.longevityleaders.com



2-3 September 2020, Nasdaq Offices, Stockholm, Sweden
www.lsxleaders.com/nordic



16 November 2020, Old Billingsgate, London, UK
www.lsxleaders.com/investival



16-17 November 2020, Old Billingsgate, London, UK
www.lsxleaders.com/digihealth



17 November 2020, The Honourable Artillery Company, London, UK
www.lsxleaders.com/lifestars



2-3 February 2021, etc. venues, 133 Houndsditch, London, UK
www.lsxleaders.com/world

Congress & Exhibition Floorplan

